Session Details

Advanced Practice Professionals (APP track) Session 2 – Novel Therapies for Treating Cancer
Thursday, May 30, 2019 03:45 PM - 05:00 PM 
Room 217
Advanced Practice Professionals Track
Co-Chairs:
Tobi Fisher, MPAS, PA-C, MD Anderson Cancer Center, United States
Megan Cornelison, MS, PA-C, MD Anderson Cancer Center, United States

This session will discuss the current state of art including Chimeric Antigen Receptor T cells and Endogenous T-cells for solid tumors and hematologic malignancies.

Speakers:

CD2-CAR-T cell for GD2-positive Malignancies
Michael Brown, MBBS, PhD, University of South Australia, Australia

Factors impacting initial response and toxicity after CD19 CAR-T cell immunotherapy
Cameron Turtle, MBBS, PhD , Fred Hutchinson Cancer Research Center, United States

Factors Impacting Initial Response and Toxicity After CD19 CAR-T Cell Immunotherapy
Cassian Yee, MD, , MD Anderson Cancer Center, United States

Megan Cornelison MS, PA-C
Supervisor, Advanced Practice Providers
MD Anderson Cancer Center
Chairman


Tobi Fisher MPAS, PA-C
Physician Assistant
MD Anderson Cancer Center
Chairman


Michael Brown MBBS, PhD
Professor
Royal Adelaide Hospital Cancer Center
Speaker


Cameron Turtle MBBS, PhD
Associate Member and Attending Physician
Fred Hutchinson Cancer Research Center
Speaker


Cassian Yee MD
Professor
MD Anderson Cancer Center
Speaker